They participate in the development of tumors as oncogenes by inducing mitogenic and survival signals, promoting tumor cell invasion and metastasis, promoting epithelial–mesenchymal transition, promoting angiogenesis, and participating in tumor recurrence and drug resistance (13). Thus, targeting FGF-2 for inhibition of tumor growth and angiogenesis was considered to be a promising therapeutic strategy. Here, FGF2 is linked to neoplasm.